Last reviewed · How we verify
Nimodipine group
Nimodipine group is a Dihydropyridine calcium channel blocker Small molecule drug developed by University Hospital Hradec Kralove. It is currently in Phase 3 development for Subarachnoid hemorrhage with cerebral vasospasm, Ischemic stroke prevention and treatment. Also known as: nimodipine, Nimotop.
Nimodipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and improved cerebral blood flow.
Nimodipine is a small molecule that acts as a mineralocorticoid receptor antagonist. It has been studied in various clinical trials for conditions such as subarachnoid hemorrhage, knee osteoarthritis, and stroke.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Nimodipine group |
|---|---|
| Also known as | nimodipine, Nimotop |
| Sponsor | University Hospital Hradec Kralove |
| Drug class | Dihydropyridine calcium channel blocker |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Neurology / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Nimodipine preferentially acts on cerebral blood vessels compared to peripheral vessels, reducing vasospasm and improving microcirculation in the brain. By blocking calcium influx into vascular smooth muscle cells, it prevents vasoconstriction and enhances oxygen delivery to ischemic brain tissue. This mechanism is particularly beneficial in conditions involving cerebral vasospasm and reduced cerebral perfusion.
Approved indications
- Subarachnoid hemorrhage with cerebral vasospasm
- Ischemic stroke prevention and treatment
Common side effects
- Headache
- Hypotension
- Flushing
- Dizziness
- Gastrointestinal disturbances
Key clinical trials
- Effect of Extracorporeal Shock Wave Therapy (ESWT) and Phonophoresis Treatment in Patients With Lateral Epicondylitis (NA)
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage (PHASE3)
- Evaluation of Extracorporeal Shockwave Therapy and Complex Decongestive Therapy Results in Patients With Lipedema (NA)
- Extracorporeal Shock-wave Therapy in Myofascial Pain Syndrome
- Investigation of the Efficiency of Radial Extracorporeal Shock Wave Therapy at Different Pulses in Carpal Tunnel Syndrome (NA)
- Chronic Plantar Fasciitis: Which is More Effective? Prolotherapy/Extracorporeal Shock Wave Therapy? (NA)
- Comparison of Short-term Effects of Extracorporeal Shock Wave Therapy, Low-level Laser Therapy and Pulsed Electromagnetic Field Therapy in Knee Osteoarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nimodipine group CI brief — competitive landscape report
- Nimodipine group updates RSS · CI watch RSS
- University Hospital Hradec Kralove portfolio CI
Frequently asked questions about Nimodipine group
What is Nimodipine group?
How does Nimodipine group work?
What is Nimodipine group used for?
Who makes Nimodipine group?
Is Nimodipine group also known as anything else?
What drug class is Nimodipine group in?
What development phase is Nimodipine group in?
What are the side effects of Nimodipine group?
What does Nimodipine group target?
Related
- Drug class: All Dihydropyridine calcium channel blocker drugs
- Target: All drugs targeting L-type voltage-gated calcium channel
- Manufacturer: University Hospital Hradec Kralove — full pipeline
- Therapeutic area: All drugs in Neurology / Cardiovascular
- Indication: Drugs for Subarachnoid hemorrhage with cerebral vasospasm
- Indication: Drugs for Ischemic stroke prevention and treatment
- Also known as: nimodipine, Nimotop
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing